Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses.
- Dangaj D Department of Oncology; Ludwig Cancer Research Center; University of Lausanne; Lausanne, Switzerland.
- Scholler N
- 2013-10-02
Published in:
- Oncoimmunology. - 2013
English
B7-H4 inhibits T-cell activation and is widely expressed by solid neoplasms. We have recently demonstrated that the expression of B7-H4 on the surface of malignant cells in vivo is inducible, and that novel anti-B7-H4 recombinant antibodies can reverse the inhibition of tumor-specific T cells. Thus, antibodies targeting the B7-H4 pathways may extend the survival of cancer patients by restoring T cell-mediated antitumor responses.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.4161/onci.25913
- PMID 24083083
- Persistent URL
- https://folia.unifr.ch/global/documents/115274
Statistics
Document views: 22
File downloads:
- fulltext.pdf: 0